In NSCLC tumors, PD-1+ macrophages are mainly stromal CD163+ macrophages and are associated with poor prognosis, suggesting once more that the phenotype and the localization of myeloid cells are likely crucial parameters to take into account for ICI biomarkers (136). Here, CD163 is linked to non-small cell lung carcinoma.